Simplified Pneumococcal Vaccination Schedules for Adults Age 50 and Over Lead to Worse Health
Journal Title: UNKNOWN - Year 2017, Vol 8, Issue 6
Abstract
Background: In 2014 the Advisory Committee on Immunization Practices (ACIP) approved a dose of 13-valent pneumococcal conjugate vaccine (PCV13) for all adults at age 65 years. This further complicated the pneumococcal vaccination schedule, which was already one of the most complicated schedules. Objective: This study documents simplified schedules that were considered and discarded by the pneumococcal working group before making the most recent recommendation. We examined the marginal cost-effectiveness of several simplified schedules for older adults (age 50+ years) when compared with current recommendations. Our primary outcome was the cost-effectiveness ratio of quality-adjusted life years to cost. Methods: We used a probabilistic model following a cohort of 50 year-olds with separate vaccination coverage and disease incidence data for healthy adults and adults at increased risk of pneumococcal disease. We compared incremental cost-effectiveness ratios from the schedule that was ultimately recommended with each potential simplified vaccination strategy. Results: Most schedules analyzed resulted in several hundred additional deaths. While several possible schedules resulted in cost savings, these cost savings were modest compared to the health costs associated with them. Conclusion: The schedule recommended by the ACIP in 2014, while complex, is the most health promoting compared to the modeled alternative schedules. The incremental cost-effectiveness ratio of the current schedule when compared to simplified alternatives is comparable to other vaccine-related interventions.
Authors and Affiliations
Charles Stoecker, Lindsay Kim, Ryan Gierke, Tamara Pilishvili
Keywords
Related Articles
- EP ID EP363367
- DOI 10.4172/2157-7560.1000373
- Views 41
- Downloads 0
Fractional Delivery: Toward a Painless, Safe and Effective Cutaneous Vaccination
Delivering vaccines into skin (Cutaneous Vaccination) is one of most promising strategies for the next generation vaccination. Cutaneous vaccination enables high vaccination efficacy harnessing the unique immunological n...
Development of an in vitro Biochemical Assay System for the Measurement of Residual Toxin Activities in Pertussis Toxin Containing Vaccines
Pertussis (whooping cough) vaccines play an essential role in immunisation programmes worldwide and the histamine sensitisation test (HIST) is currently the official batch-release test for acellular pertussis containing...
Immunization Rates and Barriers to Influenza Vaccine Access in the Community Pharmacy
The Advisory Committee on Immunization Practices (ACIP) recommends the annual influenza vaccine for everyone 6 months of age and older [1]. Annual flu vaccination is the most effective way to prevent influenza and its co...
Primary Immunization among Children in Malaysia: Reasons for Incomplete Vaccination
Objective: Incomplete primary immunization against vaccine preventable diseases is a significant public health problem. This study aimed to identify population at-risk for incomplete immunization and their associated fac...
Virus Inactivation Using a High Dose of Gamma-Irradiation: A Possible Approach for Safer Vaccines Against Highly Infectious Agents
Vaccination is arguably the most crucial protection strategy available against infectious agents. The World Health Organisation (WHO) estimates immunisations against the pathogens diphtheria, pertussis, tetanus, and meas...